Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.380
-0.120 (-2.67%)
Mar 27, 2026, 4:00 PM EDT - Market closed
Bolt Biotherapeutics Revenue
In the year 2025, Bolt Biotherapeutics had annual revenue of $7.70M with 0.07% growth. Bolt Biotherapeutics had revenue of $2.50M in the quarter ending December 31, 2025.
Revenue (ttm)
$7.70M
Revenue Growth
+0.07%
P/S Ratio
1.09
Revenue / Employee
$192,375
Employees
40
Market Cap
8.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 5.00K | 0.07% |
| Dec 31, 2024 | 7.69M | -186.00K | -2.36% |
| Dec 31, 2023 | 7.88M | 2.15M | 37.48% |
| Dec 31, 2022 | 5.73M | 4.47M | 354.68% |
| Dec 31, 2021 | 1.26M | 1.03M | 445.45% |
| Dec 31, 2020 | 231.00K | 16.00K | 7.44% |
| Dec 31, 2019 | 215.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioAtla | 11.00M |
| CollPlant Biotechnologies | 2.48M |
| SeaStar Medical Holding | 881.00K |
| Iterum Therapeutics | 390.00K |
| Addex Therapeutics | 198.82K |
| Kiora Pharmaceuticals | 20.00K |
BOLT News
- 15 days ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Bolt Biotherapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
- 8 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 months ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 months ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 11 months ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire